CNBC January 26, 2025
Key Points
– Pharmaceutical companies appear to be cautiously optimistic that brighter days are ahead under a Trump administration, following years of Joe Biden’s hardline stance on the industry.
– Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation and patient access to treatments.
– Those companies are particularly eager to see changes to a provision of Biden’s Inflation Reduction Act that allows Medicare to negotiate drug prices with manufacturers.
Pharmaceutical companies appear to be hopeful about their growth under a Trump administration, after former President Joe Biden took a hardline stance on the industry for the last four years.
Like his predecessor, President Donald Trump will make...
Today's Sponsors
Today's Sponsor